GSEP
CRL icon

Golden State Equity Partners’s Charles River Laboratories CRL Stock Holding History

Golden State Equity Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29
Closed -$5K – 624
2026
Q1 		$5K Buy
+29
New +$5.38K ﹤0.01% 1473
2024
Q4 		– Sell
-82
Closed -$16.1K – 540
2024
Q3 		$16.1K Buy
+82
New +$17K ﹤0.01% 661

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Golden State Equity Partners's CRL Position: Q2 2026 in Review

Golden State Equity Partners sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 29 shares — an estimated $5K sold.

Golden State Equity Partners first reported a position in CRL in Q3 2024 and held it in 2 quarters. The position peaked at $16.1K in Q3 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Golden State Equity Partners reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 29 Charles River Laboratories shares in Q2 2026, an estimated $5K.
  • Golden State Equity Partners first reported a position in Charles River Laboratories in Q3 2024 and held it in 2 quarters.
  • Golden State Equity Partners's Charles River Laboratories position peaked at $16.1K in Q3 2024.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.